Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

By F. Torriani, M. Rodríguez-Torres, J. Rockstroh, E. Lissen, J. González-García, A. Lazzarin, G. Carosi, J. Sasadeusz, C. Katlama, J. Montaner and 6 more. New England Journal of Medicine, 2004

1,277 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/1ba1fc6b079928f5cdf502badf704d5c68b8d0a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Aasld Idsa Hcv Guidance Panel

Citations in the corpus

• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. (2004, background): “(%) Improving 4 (11) 10 (15) 5 (20) 11 (14)”
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, result): “Persons coinfected with HIV/HCV also had lower responses to PEG-IFN and RBV than those with HCV infection alone, an observation largely explained by the higher baseline HCV RNA levels.(113,114) However, with the advent of DAAs, differences in treatment responses between monoand coinfected patients h”
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection (2011, neutral): “Rate of relapse‡ 37/162 (23) 21/232 (9) <0.”